Loading
Jun Ma is the world's leading nasopharyngeal carcinoma trialist, whose randomised studies define induction chemotherapy and immunotherapy for the disease.
Jun Ma is Professor of Radiation Oncology and leads the nasopharyngeal carcinoma programme at Sun Yat-sen University Cancer Center in Guangzhou. He is the world's leading nasopharyngeal carcinoma trialist, and his randomised studies established gemcitabine plus cisplatin induction chemotherapy, defined the role of Epstein-Barr virus DNA in risk stratification and, with colleagues in JUPITER-02, tested PD-1 blockade in the disease. His publications include the trial of gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma. His work, built on modern intensity-modulated radiotherapy, shapes international guidelines for this cancer.
| Title | Journal | Year |
|---|---|---|
| Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma | NEJM | 2019 |
Shares Sun Yat-sen University Cancer Center, Head and neck squamous cell carcinoma.
Shares Sun Yat-sen University Cancer Center, Head and neck squamous cell carcinoma.
Shares JUPITER-02, Sun Yat-sen University Cancer Center, Head and neck squamous cell carcinoma.
Shares Sun Yat-sen University Cancer Center, Head and neck squamous cell carcinoma.
Shares Sun Yat-sen University Cancer Center, Head and neck squamous cell carcinoma.
Shares Sun Yat-sen University Cancer Center, IMRT / IGRT (modern external beam).
Shares Sun Yat-sen University Cancer Center, Head and neck squamous cell carcinoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/